سعر انليتير 4 مجم 14 كيس 2025

Inletair 4 mg (Organopharma): montelukast 4 mg oral granules in sachets, 14 sachets; a leukotriene receptor antagonist for young children.

• Prophylaxis and chronic treatment of asthma (from 12 months of age); not for acute asthma attacks.Population: Adults and children from 12 monthsDailyMed (U.S. National Library of Medicine)
• Relief of symptoms of seasonal (from 2 years) and perennial (from 6 months) allergic rhinitis, reserved for patients with inadequate response or intolerance to alternative therapies.Population: Adults and childrenDailyMed (U.S. National Library of Medicine)

• Most common (>=5% and more than placebo, all ages): upper respiratory infection, fever, headache, pharyngitis, cough, abdominal pain, diarrhoea, otitis media, influenza, rhinorrhoea, sinusitis and otitis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to any component of the product.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning - serious neuropsychiatric events (agitation, depression, sleep disturbance, suicidal thoughts and behaviour) have been reported; discuss benefits and risks, and for allergic rhinitis reserve for patients who respond inadequately to or cannot tolerate alternatives; stop and seek care if symptoms occur.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Not for treatment of acute asthma attacks; do not abruptly substitute for inhaled or oral corticosteroids; patients with aspirin sensitivity should continue avoiding aspirin/NSAIDs; systemic eosinophilia/eosinophilic granulomatosis with polyangiitis may occur (often with steroid reduction).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Phenobarbital, rifampin (CYP3A4 inducers)Reduce montelukast exposure; no dose adjustment recommended but monitor clinically.DailyMed (U.S. National Library of Medicine)

• Available data from published prospective and retrospective cohort studies have not established a drug-associated risk of major birth defects; poorly controlled asthma carries maternal and fetal risks.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Montelukast is present in human milk; available data do not suggest a significant risk to the breastfed infant; weigh benefits against the mother's need for the drug.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Montelukast: Selectively binds the cysteinyl leukotriene CysLT1 receptor, inhibiting leukotriene-mediated airway oedema, smooth-muscle contraction and inflammation.